See more : Kintor Pharmaceutical Limited (9939.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Silk Road Medical, Inc (SILK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silk Road Medical, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- TALi Digital Limited (TD1.AX) Income Statement Analysis – Financial Results
- H World Group Limited (1179.HK) Income Statement Analysis – Financial Results
- Exxaro Tiles Limited (EXXARO.NS) Income Statement Analysis – Financial Results
- VIP Clothing Limited (VIPCLOTHNG.BO) Income Statement Analysis – Financial Results
- Revive Therapeutics Ltd. (RVVTF) Income Statement Analysis – Financial Results
Silk Road Medical, Inc (SILK)
About Silk Road Medical, Inc
Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products include ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 177.13M | 138.64M | 101.48M | 75.23M | 63.35M | 34.56M | 14.26M |
| Cost of Revenue | 50.05M | 37.88M | 25.45M | 21.29M | 15.93M | 10.87M | 5.13M |
| Gross Profit | 127.09M | 100.76M | 76.03M | 53.94M | 47.43M | 23.68M | 9.13M |
| Gross Profit Ratio | 71.75% | 72.68% | 74.92% | 71.70% | 74.86% | 68.53% | 64.03% |
| Research & Development | 41.32M | 36.45M | 27.11M | 21.27M | 12.27M | 10.26M | 7.24M |
| General & Administrative | 144.57M | 115.97M | 96.17M | 75.33M | 62.86M | 34.82M | 20.26M |
| Selling & Marketing | 461.00K | 347.00K | 221.00K | 194.00K | 362.00K | 186.00K | 218.00K |
| SG&A | 145.03M | 116.32M | 96.39M | 75.52M | 63.22M | 34.82M | 20.26M |
| Other Expenses | 442.00K | -190.00K | -23.00K | -80.00K | -21.05M | -12.06M | 2.93M |
| Operating Expenses | 186.36M | 152.77M | 123.50M | 96.80M | 75.49M | 45.08M | 27.50M |
| Cost & Expenses | 236.41M | 190.64M | 148.94M | 118.09M | 91.42M | 55.95M | 32.63M |
| Interest Income | 9.96M | 2.53M | 198.00K | 1.10M | 1.66M | 189.00K | 34.00K |
| Interest Expense | 6.87M | 5.10M | 2.52M | 4.41M | 4.95M | 4.36M | 3.94M |
| Depreciation & Amortization | 3.79M | 3.17M | 1.92M | 1.39M | 1.29M | 517.00K | 128.72K |
| EBITDA | -45.08M | -46.74M | -45.55M | -41.47M | -46.17M | -32.75M | -18.25M |
| EBITDA Ratio | -31.32% | -35.82% | -46.61% | -55.51% | -41.68% | -94.78% | -107.20% |
| Operating Income | -59.27M | -52.00M | -47.47M | -42.86M | -28.07M | -21.40M | -18.37M |
| Operating Income Ratio | -33.46% | -37.51% | -46.78% | -56.97% | -44.30% | -61.91% | -128.87% |
| Total Other Income/Expenses | 3.53M | -3.01M | -2.34M | -4.51M | -24.35M | -16.24M | -982.00K |
| Income Before Tax | -55.74M | -55.01M | -49.81M | -47.37M | -52.42M | -37.63M | -19.36M |
| Income Before Tax Ratio | -31.47% | -39.68% | -49.09% | -62.96% | -82.73% | -108.89% | -135.76% |
| Income Tax Expense | 43.00K | 3.01M | 576.00K | 3.02M | 3.66M | -11.87M | 6.87M |
| Net Income | -55.74M | -58.02M | -50.39M | -50.39M | -56.07M | -37.63M | -19.36M |
| Net Income Ratio | -31.47% | -41.85% | -49.65% | -66.98% | -88.51% | -108.89% | -135.76% |
| EPS | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| EPS Diluted | -1.44 | -1.62 | -1.45 | -1.53 | -2.44 | -1.31 | -0.80 |
| Weighted Avg Shares Out | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
| Weighted Avg Shares Out (Dil) | 38.80M | 35.78M | 34.64M | 32.97M | 22.96M | 28.71M | 24.05M |
Why Is Silk Road Medical (SILK) Stock Down 40% Today?
Silk Road Medical (NASDAQ: SILK ) stock is falling hard on Wednesday after the medical device company released preliminary earnings results for Q3 2023. A press release from Silk Road Medical reveals that the company is expecting revenue for the third...
Silk Road Medical Stock Sinks. Here's Why Citi Says Sell.
Two pieces of news are weighing on shares of the medical devices company.
Novo Nordisk shares rise, Silk Road Medical stock slumps and other movers
Shares of Thor Industries Inc. THO rose 2% after the RV maker said its board authorized a 7% dividend increase to 48 cents a share.
Silk Road Medical stock falls following outlook, CEO's retirement
Silk Road Medical Inc. SILK, -0.71% shares dropped in the extended session Tuesday after the medical device company updated its forecast and said its chief executive was retiring. The company forecast third-quarter revenue of about $44.4 million, and full-year revenue...
Silk Road Medical Announces Preliminary Third Quarter 2023 Revenue and Provides Revised 2023 Outlook
SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced preliminary revenue for the quarter ended September 30, 2023, and provided an...
Silk Road Medical Announces Retirement of CEO Erica Rogers
Working with Leading Executive Search Firm to Identify Successor SUNNYVALE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that CEO Erica...
Silk Road Medical to Present at the CL King 21st Annual Best Ideas Conference
SUNNYVALE, Calif., Sept. 04, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that management will present at the CL King 21st Annual Best Ideas...
Silk Road Medical to Present at the UBS MedTech, Tools and Genomics Summit
SUNNYVALE, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the company will participate in the upcoming UBS MedTech, Tools and...
Silk Road Medical, Inc. (SILK) Q2 2023 Earnings Call Transcript
Silk Road Medical, Inc. (NASDAQ:SILK ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Erica Rogers - Chief Executive Officer Lucas Buchanan - Chief Financial Officer & Chief Operating Officer...
Silk Road Medical (SILK) Reports Q2 Loss, Tops Revenue Estimates
Silk Road Medical (SILK) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.44 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports